Supplemental Content

Save items

Add to Favorites

loading

Related citations in PubMed

Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation. [Leuk Res. 2010]
Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation.
Faber E, Mojzikova R, Plachy R, Rozmanova S, Stastny M, Divoka M, Jarosova M, Indrak K, Divoky V. Leuk Res. 2010 Apr; 34(4):e91-3. Epub 2009 Oct 6.

Review Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. [Clin Ther. 2007]
Review Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M. Clin Ther. 2007 Nov; 29(11):2289-308.

F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib. [Leuk Res. 2011]
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib.
Oyekunle AA, Castagnetti F, Gugliotta G, Soverini S, Baccarani M, Rosti G. Leuk Res. 2011 Jul; 35(7):e118-20. Epub 2011 Apr 12.

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors. [Hematol Oncol. 2010]
Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Kim WS, Kim D, Kim DW, Kweon IY, Kim SH, Goh HG, Park SH, Lee J. Hematol Oncol. 2010 Jun; 28(2):82-8.

Review Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. [Cell Cycle. 2011]
Review Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.
Hochhaus A, La Rosée P, Müller MC, Ernst T, Cross NC. Cell Cycle. 2011 Jan 15; 10(2):250-60. Epub 2011 Jan 15.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.

Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Search details

21605905[uid]

See more...

Recent activity

Clear Turn Off Turn On

Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are ...
Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: is that true for all the patients?
Leuk Res. 2011 Sep ;35(9):e145-6. doi: 10.1016/j.leukres.2011.04.025. Epub 2011 May 24 .

PubMed

21605905[uid] (1)
PubMed

Your browsing activity is empty.
m=Eskazan%20AE%5BAuthor%5D&cauthor=true&cauthor_uid=21605905">Eskazan AE, Soysal T, Erbilgin Y, Ozbek U, Ferhanoglu B.

Save items

Related citations in PubMed

Related information

Search details

Recent activity

Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: is that true for all the patients?

Comment on

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Supplemental Content